![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.globenewswire.com/news-release/2023/06/03/2681514/0/en/Apexigen-Announces-Phase-2-Data-Evaluating-Sotigalimab-its-CD40-Agonist-Antibody-in-Combination-with-Doxorubicin-in-Patients-with-Advanced-Soft-Tissue-Sarcoma-Presented-at-the-Amer.html
https://www.globenewswire.com/news-release/2023/01/19/2591742/0/en/Apexigen-Announces-New-Phase-2-Data-Evaluating-Sotigalimab-its-CD40-Agonist-Antibody-at-ASCO-Gastrointestinal-Cancers-Symposium-2023.html
https://www.globenewswire.com/news-release/2022/09/10/2513554/0/en/Apexigen-Presents-New-Data-from-a-Phase-2-Trial-Evaluating-its-CD40-Antibody-Sotigalimab-in-Combination-with-Neoadjuvant-Chemoradiation-in-Patients-with-Resectable-Esophageal-and-G.html
https://ir.apexigen.com/news-releases/news-release-details/apexigen-announces-new-data-phase-2-trial-evaluating-its-cd40-1
https://www.globenewswire.com/news-release/2022/06/06/2456670/0/en/Apexigen-Announces-Nature-Medicine-Publication-and-ASCO-Presentation-on-the-Phase-2-PRINCE-Trial-Showcasing-Distinct-Biosignatures-in-Metastatic-Pancreatic-Cancer-Patients-Treated-.html
https://www.globenewswire.com/news-release/2022/04/12/2421457/0/en/Apexigen-Announces-New-Data-from-a-Phase-2-Trial-Evaluating-its-CD40-Antibody-Sotigalimab-in-Combination-with-Pembrolizumab-in-Patients-with-Metastatic-Melanoma-Presented-at-the-AA.html
https://www.globenewswire.com/news-release/2021/11/12/2333390/0/en/Apexigen-Announces-New-Phase-2-Clinical-Data-on-CD40-Antibody-Sotigalimab-at-the-SITC-2021-Annual-Meeting.html